<div id="readability-page-1"><div>By Colin Kellaher Bristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR T-cell therapy Breyanzi in a subtype of non-Hodgkin lymphoma. Bristol Myers late Thursday said the approval covers Breyanzi for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. The Princeton, N.J., biopharmaceutical company said the green light makes Breyanzi the only CAR T-cell therapy approved by the FDA for five cancer types and the only one approved for those with relapsed or refractory marginal zone lymphoma. CAR T-cell therapy involves genetically engineering a patient's own T cells to attack cancer cells. Breyanzi generated worldwide revenue of $966 million in the first nine months of 2025. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires12-05-25 0631ET</div></div>

百时美施贵宝

百时美施贵宝已获得美国食品药品监督管理局（FDA）对其 CAR T 细胞疗法 Breyanzi 的扩展批准，用于治疗成人复发性或难治性边缘区淋巴瘤。这使得 Breyanzi 成为唯一获得批准用于五种癌症类型的 CAR T 细胞疗法，包括这一特定的淋巴瘤亚型。该疗法涉及对患者的 T 细胞进行基因工程改造，以靶向癌细胞。Breyanzi 在 2025 年前九个月的收入达到了 9.66 亿美元

百时美施贵宝获得 FDA 对 Breyanzi 的扩大适应症批准